Yong-Qing Wang
Overview
Explore the profile of Yong-Qing Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
1217
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang Y, Li T, Feng H, Lv L, Tang T, Lin Z, et al.
Small
. 2024 Nov;
21(3):e2407443.
PMID: 39544157
The application of metal-organic frameworks (MOFs) in the electro-catalysis of heterogeneous structures is limited by the problems of low electrical conductivity and poor mechanical strength due to the complex synthesis...
2.
Simultaneous Determination of Ripretinib and Its Desmethyl Metabolite in Human Plasma Using LC-MS/MS
Qian Z, Wang P, Wang Z, Zhao Y, Du T, Xu H, et al.
Ther Drug Monit
. 2024 Aug;
PMID: 39115815
Background: Ripretinib, a recently developed tyrosine kinase inhibitor with switch-control abilities, can inhibit both primary and secondary activation of KIT(KIT proto-oncogene receptor tyrosine kinase) and platelet-derived growth factor receptor alpha...
3.
Ge W, Du T, Wang C, Sun L, Wang Y
Biochem Pharmacol
. 2024 May;
225:116278.
PMID: 38740223
Calcium (Ca) acts as a second messenger and constitutes a complex and large information exchange system between the endoplasmic reticulum (ER) and mitochondria; this process is involved in various life...
4.
Zhang L, Liu Y, Huang Q, Zhang H, Xie L, Chen J, et al.
Naunyn Schmiedebergs Arch Pharmacol
. 2024 May;
397(10):7639-7647.
PMID: 38691150
Urinary tract infection (UTI) is one of the most prevalent bacterial infectious diseases worldwide. However, the resistance of urinary pathogens to other UTI antibiotics such as trimethoprim and trimethoprim/sulphamethoxazole increased....
5.
Guo Y, Du T, Yang Y, Zhao Y, Chen X, Ma H, et al.
Ther Drug Monit
. 2024 Mar;
46(5):634-641.
PMID: 38531816
Background: Ibrutinib and zanubrutinib are Bruton tyrosine kinase inhibitors used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. Dihydroxydiol ibrutinib (DHI) is an active metabolite of...
6.
Yang Y, Qian Z, Zhao Y, Chen X, Huang Q, Guo Y, et al.
Biomed Chromatogr
. 2023 Sep;
37(12):e5738.
PMID: 37724003
We developed and validated sensitive MS/MS methods for the determination of venetoclax, an oral selective B-cell lymphoma-2 inhibitor, in human plasma and cerebrospinal fluid (CSF). Acetonitrile was used as protein...
7.
Zhao Y, Guo Y, Chen X, Yang Y, Ma H, Wang Y, et al.
Ther Drug Monit
. 2023 May;
45(5):599-605.
PMID: 37199420
Background: Orelabrutinib is a second-generation Bruton tyrosine kinase inhibitor that improves the management of B-cell malignancies. The objective of this study was to develop and validate an LC-MS/MS method for...
8.
Wen S, Ma H, Chen X, Zhao Y, Liu Y, Li Y, et al.
Bioanalysis
. 2023 Feb;
14(23):1497-1508.
PMID: 36825935
Caffeine is a central nervous system stimulant, used to treat apnea of prematurity. A hydrophilic interaction chromatography-tandem mass spectrometry (HILIC-MS/MS) approach was developed to detect caffeine, paraxanthine, theophylline and theobromine...
9.
Sun L, Zhao Y, Qian Z, Chen X, Ma H, Guo Y, et al.
Molecules
. 2023 Feb;
28(3).
PMID: 36770870
Ibrutinib, orelabrutinib, and zanubrutinib are all Bruton's tyrosine kinase inhibitors, which have greatly improved the treatment of B-cell malignancies. In this study, an LC-MS/MS method was developed and validated for...
10.
Wang Y, Li L, Li G
J Gastrointest Oncol
. 2023 Jan;
13(6):2863-2873.
PMID: 36636080
Background: There are still clinical controversy on the efficacy and safety of endoscopic resection (ER) and laparoscopic resection (LR) in the treatment of gastrointestinal stromal tumors (GISTs). The present study...